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Conclusive proof that blood coagulation involved other factors in addition to those included in the classical theory was first provided by Owren's (I944, I947) discovery of factor V, although it is clear that Nolf's (I908) work, which had largely been overlooked, had anticipated Owren's discovery by many years. Owren's factor V, which was soon to be rediscovered independently by Fantl and Nance (I946) and by Ware, Guest and Seegers (I947), stimulated widespread interest in the factors concerned in blood coagulation with the result that numerous new coagulation factors, some hypothetical and inadequately supported by experimental evidence, have been postulated. It is the purpose of this short article to describe very briefly the more important properties of the factors included in the classical theory of blood coagulation; to describe the action pf those newly discovered factors whose existence seems adequately established; and to ProthrombJn LlThromboplastin outline some of the more important observations that led to their discovery. Finally an attempt will be made to show how they, and the older established factors, interact to cause coagulation of the blood. As many of the coagulation factors have been given different names by different workers, a list of some of the more commonly used synonyms is given in (Owren) FACTOR VII (Koller) Thrombogen (Nolf) Stable component (Stefanini) Labile factor (Quick) Co-factor V (Owren) The active principle of the extracts, thromboplastin, is particulate, and can be removed by centrifugation at relatively low speeds (31,000 g.) (Chargaff et al., I944) . It can be obtained from almost any tissue in the body, brain and lung being the most commonly used. Thromboplastin will accelerate clotting even when diluted as much as I:100,000. It seems probable, therefore, that it acts as a catalyst. Thromboplastin will not clot fibrinogen solutions or preparations of plasma from which the prothrombin has been removed.
Plasma Thromboplastin Blood will clot in glass vessels without admixture with tissue extracts and must therefore, according to the classical theory, contain thromboplastin. It has generally been believed that this came from the platelets. These, however, contain relatively little, but as will be shown later, they are essential for normal thromboplastin formation.
Prothrombin and Thrombin
These have been prepared in a highly purified state by Seegers, McClaughry and Fahey (I950). They are proteins. go per cent. of the prothrombin moves electrophoretically with a mobility of a, globulin. The mobility of thrombin isslightly less. Purified prothrombinwis converted into thrombin when dissolved in 25 per cent. sodium citrate. It therefore seem&;reasonabre to conclude that prothrombin contains all the structural material needed for the formation of thrombin (Seegers et al., 1950) . The action of thrombin in converting fibrinogen to fibrin appears to be enzymatic, for thrombin will convert many times its weight of fibrinogen. This actiorn is accelerated by calcium (Biggs and Macfarlane, I953a) , and by platelet extracts (Ware, Fahey and Seegers, 1948 this patient's plasma lacked a substance which is present in normal plasma and which is left in the plasma after removal of the prothrombin. Owren called this substance factor V. He described a method for its partial purification and showed that it was necessary for the rapid conversion of prothrombin to thrombin, and that it disappeared rapidly from the blood after clotting. The prolonged prothrombin time observed with the blood of his patient was clearly due to the slow and incomplete formation of thrombin resulting from the absence of factor V from the plasma.
Several other cases of factor V deficiency have now been described (Frank, Bilhan and Ekren, 1950 Cosgriff and Leifer, 1952; Owren, 1953) . In some of these cases there was a familial incidence of the disease.
Shortly after Owren had announced his discovery, Fantl and Nance (1946) and Ware, Guest and Seegers (1947) , working independently with purified preparations of prothrombin, described experiments which demonstrated the existence of a factor required for the rapid conversion of prothrombin to thrombin. These workers found that although prothrombin prepared by salt precipitation rapidly formed thrombin in the presence of calcium and thromboplastin, yet prothrombin prepared by adsorption on to aluminium hydroxide and subsequent elution, was only converted to thrombin very slowly. The rate of conversion could be accelerated by the addition of a small quantity of the plasma from which the prothrombin had been adsorbed. The factor responsible was partially purified by both groups of workers. Fantl and Nance (I948) called the factor prothrombin accelerator, while Ware and Seegers (I948) gave it the name Ac globulin. There seems little doubt that these factors are identical with Owren's factor V, and Owren's term will therefore be used hereafter. The labile factor which disappears from oxalated plasma on storage, and which was described by Quick in 1943, is probably also identical with factor V, although it must be stated that the clotting defect produced by storage is not a clearly defined entity, and that storage almost certainly alters factors other than factor V in plasma. Ware, Fahey and Seegers (1948) have shown that platelets, as well as plasma, have factor V activity.
Factor VII
That there is another factor in addition to factor V which is responsible for accelerating the conversion of prothrombin to thrombin was first suggested by Owen and Bollman (1948 (Owren, 1947) and also because factor V is not significantly reduced in the plasma of patients receiving dicoumarol (Owren, I95ob) . The factor described by Owen and Bollman appears, therefore, to be a further prothrombin conversion factor.
In 1949, de Vries, Alexander and Goldstein observed that oxalated serum, in the presence of calcium and thromboplastin, accelerates the coagulation of oxalated plasma. This occurred if the oxalated plasma was diluted with plasma which had been adsorbed with barium sulphate to remove most of its prothrombin whilst leaving an excess of factor V. They therefore considered that the serum contained a new coagulation factor which they have partially purified (Alexander. Goldstein and Landwehr, 1950) , and which they call serum prothrombin conversion accelerator (S.P.C.A.). They showed that dicoumarol causes a reduction in both plasma prothrombin and the serum prothrombin conversion accelerator (Alexander, de Vries and Goldstein, 1949) . In 1950 Owren (195oa) showed that thrombin was formed when human serum was added to Seitz filtered ox plasma in the presence of calcium and thromboplastin. He thought at first that the prothrombin must be in the serum but later showed that it was in the ox plasma which had been inadequately filtered (Owren, 195oa; 195I) . This remaining prothrombin was not converted to thrombin by calcium, thromboplastin and factor V alone. Owren therefore concluded that the serum must contain a further factor necessary for prothrombin conversion, and that this factor had been adsorbed from the plasma by Seitz filtration. It is also adsorbed by aluminium hydroxide (Biggs, Douglas and Macfarlane, 1953a ). Owren called this factor Convertin. It seems almost certain that it is identical with the factor described by Owen and Bollman (1948) and the serum prothrombin conversion accelerator of his coworkers (1949, 1950 ).
Koller and his colleagues (1951, 1952) have repeated Owren's experiments and have shown conclusively that this factor accelerates the conversion of prothrombin to thrombin. They call it factor VII, factor VI being the name given by Owr rn to a hypothetical substance derived from factor V.
The importance of this factor, which will hereafter be referred to as factor VII, was finally established by Alexander and his co-workers (I95I) who described a patient with a haemorrhagic syndrome apparently due to a congenital deficiency of the factor. The disease was characterized by a normal whole blood clotting time and a prolonged one-stage prothrombin time which was corrected in vitro by the addition of crudely purified factor VII and temporarily, in vivo, by the intravenous administration of human serum. The factor V content of the patient's plasma was shown to be normal. Similar cases have recently been reported by Beaumont and Bernard (I953) and by Jiirgens (I953); and Owren (I953) has described a family of which several members were affected by this condition.
Further studies have shown that deficiency of this factor is the main abnormality caused by tromexan therapy (Douglas, I953). It is also reduced in advanced liver disease and in the newborn (de Nicola, 1953 (Biggs et al., I952) or barium sulphate (Rosenthal et al., 1953) . It occurs mainly in Cohn's plasma fraction I, which also contains the fibrinogen (Cohn, I946) . It will be referred to below as the antihaemophilic globulin. Factor V (Owren, 1947) and factor VII (Owren, I95oa) (Biggs et al., 1952) , Poole (1953), Lewis and Ferguson (1953) and by Cramer, Matter and Loeliger (i953).
The clinical picture in all these cases was indistinguishable from that of haemophilia. The condition is inherited as a sex-linked recessive character, although sporadic cases occur. As in haemophilia, the coagulation time is usually prolonged. The one-stage prothrombin time is normal, although the conversion of prothrombin to thrombin during coagulation is reduced. The condition is not due to, a deficiency of antihaemophilic globulin, for the plasma of these patients reduces the clotting time of haemophilic plasma. The clotting time of the plasma of these patients is reduced by normal and by haemophilic plasma, but not by antihaemophilic globulin (Biggs et al., 1952) .
Investigation of the factor concerned shows that, unlike anti-haemophilic globulin, it is present in large amounts in normal serum. It is removed from normal serum or plasma by adsorption on to aluminium hydroxide, or by Seitz filtration , or by adsorption on to barium sulphate (Rosenthal et al., 1953) . In these respects it resembles factor VII. That it is distinct from factor VII is shown by the following observations: (i) Its deficiency does not cause prolongation of the one-stage prothrombin time.
(2) Serum from patients deficient in the factor corrects the coagulation defect of the plasma of patients receiving tromexan. (3) The coagulation defect in patients deficient in the factor is corrected by some serum samples from patients receiving tromexan intervals by observing the coagulation time of samples of normal oxalated plasma to which calcium chloride and aliquot quantities of the abovementioned mixture are added. As the mixture contains no significant amount of prothrombin, the coagulation of the normal plasma will be due almost entirely to the thromboplastin developed in the mixture, and the coagulation times will be inversely proportional to the concentration of thromboplastin. Under these conditions thromboplastin forms gradually over a period of 4 to 5 minutes, but when fully developed has a potency at least as great as that of a potent brain extract. By observing the coagulation times with different dilutions of this thromboplastin, a thromboplastin dilution curve can be drawn (Fig. 2) relating clotting time to thromboplastin concentration. The diagram (Fig. 3) shows the thromboplastin concentrations generated in 40 different tests. After five minutes, when the thromboplastin generated in the mixtures was maximal, the mean clotting time of normal plasma to which the mixture was added was less than io seconds. This is as short, if not cently described factors X and plasma thromboplastin antecedent (P.T.A.), and it seems probable that these are also necessary for thromboplastin formation.
Coagulation Factors in the Platelets
The thromboplastin generation test has shown that platelets are necessary for the formation of plasma thromboplastin. Three coagulation factors have been extracted from platelets:
Platelet factor I. This was first described by Ware, Fahey and Seegers in 1948. It is found, together with platelet factor II, in watery extracts of platelets. These two factors have since been separated by van Creveld and Paulssen (I95I). Platelet factor I has an activity resembling that of factor V of normal plasma, but unlike factor V it is particulate and can be made to sediment by centrifuging at about 32,000 g.
Platelet factor II. This accelerates the clotting of fibrinogen by thrombin.
Platelet factor III. This is insoluble in water. When suspended in plasma it antagonizes the action of heparin and has thromboplastic activity. This factor was first described by van Creveld and Paulssen (I95I, 1952) .
So far no attempt appears to have been made to discover which of these factors is utilized in the generation of plasma thromboplastin. The properties of factors I and III suggest that these must be required, but it is not known whether these alone are sufficient or whether the platelets have still other properties which are also involved.
In thrombocytopenic purpura, presumably because there are insufficient platelets to permit normal thromboplastin formation, prothrombin conversion is incomplete. Apart from this, the association of a haemorrhagic disease with an abnormality of the platelets has been reported by (Patton, Ware and Seegers, 1948) . It seems clear, therefore, that both platelets and contact with a suitable surface are necessary, and it may be surmised that contact precipitates platelet disintegration and so initiates the formation of plasma thromboplastin.
In haemophilia, in which the plasma is d2ficient in antihaemophilic globulin, the blood may not clot for an hour or more even when it is in contact with glass. Moreover, the platelets in haemophilic blood disintegrate much less rapidly during coagulation than do normal platelets in normal blood (Howell and Cekada, 1926) . As plat 1ats from haemophilic blood, when suspended in normal plasma, in glass vesszls, disrupt normally during coagulation (Patek and Stetson, I936) , it would seem that the platelets in haemophilia are probably normal, and that antihaemophilic globulin may be concerned with the normal disruption of platelets when these come into contact with a suitable surface.
Further evidence of the importance of contact is provided by the observation that the capacity of serum to accelerate prothrombin conversion is reduced if coagulation is delayed by the use of silicone lined apparatus (Alexander, de Vries and Goldstein, 1949; ).
This observation was originally interpreted as indicating that factor VII must exist in plasma as a relatively inactive precursor which was activated by contact, for at this time factor VII was the only conversion factor known which existed in equal concentration in serum and plasma (the concentrations of both factor V (Owren, i947) and antihaemophilic globulin (Graham et al., I951) fall rapidly after coagulation). Subsequently it wasr realized that P.T.C. (Christmas factor) and probably the recently postulated factors X and plasma thromboplastin antecedent (P.T.A.) also exist in high concentration in serum. More recent work has indicated that contact probably has no effect on factor VII (Biggs and Macfarlane, I953b) , and that it activates one or more of the other factors found in serum.
Naturally Occurring Inhibitors ofCoagulation Antithrombin
Normal blood, in addition to its complex mechanisms for producing thrombin, also contains powerful mechanisms for neutralizing it. It has been calculated, from the results of experiments on the addition of purified thrombin to plasma, that X ml. of normal plasma is capable of neutralizing rapidly the amount of thrombin that would be required to clot 2,000 ml. of blood in I5 seconds ).
Thrombin inactivation depends upon two mechanisms:
I. Adsorption on to fibrinogen. This is the cause of the immediate inactivation of thrombin. The thrombin is not destroyed and can be recovered after lysis of the fibrin (Klein and Seegers, 1950) .
2. Neutralization by a constituent of normal plasma, antithrombin, which, except with low concentrations of thrombin, appears to react stoichiometrically with thrombin rendering it inert (Klein and Seegers, 1950) . Heparin
Heparin is a powerful anticoagulant, and although it is not present in the blood in measurable quantity, it can be extracted from most of the tissues of the body, particularly the liver and lungs. There is evidence that it arises from the mast cells. These cells are commonly found along the capillaries suggesting perhaps that they may have some action in preventing local capillary thromboses.
Heparin is inactive in the absence of the albumin fraction of the plasma which contains a substance essential for its action (Quick, 1938) . It seems probable that this substance is antithrombin (Lyttleton, 1950 ).
Heparin appears to have two main actions: i. It increases the adsorption of thrombin by fibrin (Klein and Seegers, I950) .
2. In association with antithrombin it combines with thrombin, greatly increasing the rate of neutralization of thrombin by antithrombin, but apparently not increasing the amount of thrombin neutralized (Biggs and Macfarlane, I953a) .
According to , when heparin is added to whole blood it delays or prevents the conversion of prothrombin to thrombin. They consider that this effect is probably due to the rapid neutralization of thrombin, this neutralization preventing the autocatalytic effect of thrombin on the development of plasma thromboplastic activity (see below). .
Plasmin
This enzyme is found in the globulin fraction of normal human plasma. Its activity is inhibited by the albumin fraction which has therefore been considered to contain a specific inhibitor ' antiplasmin.' Plasmin normally exists in the blood in the form of an inactive precursor ' plasminogen.' It can be activated by separation from the albumin fraction of plasma or by the addition to plasma of group.bmj.com on October 19, 2017 -Published by http://pmj.bmj.com/ Downloaded from chloroform or bacterial filtrates, the most commonly used being streptokinase which is obtained from certain strains of p-haemolytic streptococci.
Plasmin causes lysis of fibrin and also destroys fibrinogen.
Fibrinolysin
Human and animal tissues contain an activator 'fibrinokinase' which activates a fibrinolysin which causes lysis of both fibrin and fibrinogen. This enzyme is also found in the globulin fraction of the plasma, but there are reasons for believing that it is not identical with plasmin (Astrup and Permin, 1948) .
Fibrinolysis Post Mortem and in Vivo
Post mortem blood in cases of sudden death is often found to be fluid, the fibrin in the postmortem clots having been liquefied by a fibrinolytic enzyme which attacks only fibrin and not fibrinogen (Mole, 1948) .
Fibrinolytic activity is induced in vivo in man by acute anxiety, severe exerciso or by injections of adrenalin (Macfarlane and Biggs, 1946; Macfarlane and Pilling, I947). The enzyme concerned differs from plasmin and fibrinolysin in that it does not digest fibrinogen (Bidwell and Macfarlane, 1951 In the absence of tissue thromboplastin, blood coagulation depends upon the production of intrinsic plasma thromboplastin, the development of which appears to be dependent upon contact with a water-wettable surface. This seems to be necessary for the disintegration of platelets. Platelet disintegration is probably accelerated by antihaemophilic globulin.
Contact is apparently also necessary for the activation of one or more of the factors, other than factor VII, found in high concentration in serum (plasma thromboplastin component (Christmas factor) and probably the recently postulated factors plasma thromboplastin antecedent and factor X). prothrombin to thrombin during coagulation. It appears to act as a catalyst in this reaction. Thrombin formation can readily be studied by aspirating aliquot quantities of blood during coagulation, and transferring them to solutions of fibrinogen. The thrombin content will be inversely proportional to the clotting time of the fibrinogen. Fig. 4 curve i shows thrombin production during the clotting of normal whole blood. There is a lag period of about 3 minutes before any thrombin appears. It then rapidly increasas in amount for a further 3 minutes and then rapidly disappears, the disappearance being due to the action of antithrombin. That thrombin can accelerate its own production is shown by the observation (Fig. 4 curve 2 (Tocantins, I952;  Owren, I952) that fibrin may increase thromboplastin production by forming an extensive waterwettable surface. Fibrin on the other hand adsorbs large quantities of thrombin, thus acting as a potent antithrombin.
In conclusion, it will be seen that blood coagulation involves several complex mechanisms. These are summarized in Fig. 6 . Some of these mechanisms tend to increase clotting and others to hold it in check. The factors which determine the resultant of these opposing forces are ill understood, and it is clear that many of the views expressed here may have to be modified as further discoveries are made in this rapidly advancing field.
The author is indebted to Dr. Rosemary Biggs and Dr. R. G. Macfarlane for their criticisms of the manuscript and to the Medical Research Council for a grant for expenses.
